.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Accenture
Harvard Business School
Medtronic
Queensland Health
Fuji
Teva
Express Scripts
Merck
Healthtrust

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,242,986

« Back to Dashboard

Which drugs does patent 9,242,986 protect, and when does it expire?


Patent 9,242,986 protects TRIUMEQ and TIVICAY and is included in two NDAs. There have been zero Paragraph IV challenges on Tivicay and Triumeq

This patent has twenty-three patent family members in twelve countries.

Summary for Patent: 9,242,986

Title:Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##
Inventor(s): Kawasuji; Takashi (Osaka, JP), Nagamatsu; Daiki (Osaka, JP)
Assignee: SHIONOGI & CO., LTD. (Osaka, JP) ViiV Healthcare Company (Research Triangle Park, NC)
Application Number:14/272,823
Patent Claim Types:
see list of patent claims
Compound;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Viiv Hlthcare
TRIUMEQ
abacavir sulfate; dolutegravir sodium; lamivudine
TABLET;ORAL205551-001Aug 22, 2014RXYesYes► Subscribe► SubscribeYY
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-002Jun 9, 2016RXYesNo► Subscribe► SubscribeYY
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-003Jun 9, 2016RXYesNo► Subscribe► SubscribeYY
Viiv Hlthcare
TIVICAY
dolutegravir sodium
TABLET;ORAL204790-001Aug 12, 2013RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,242,986

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,624,023Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
9,365,587Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
8,754,214Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,242,986

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2527451► Subscribe
Russian Federation2011121785► Subscribe
Mexico2011006241► Subscribe
South Korea20170038116► Subscribe
South Korea101733625► Subscribe
South Korea20110094336► Subscribe
Japan6130891► Subscribe
Japan2016041727► Subscribe
Japan5848595► Subscribe
Japan2012131791► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
AstraZeneca
Baxter
Fuji
Accenture
Cantor Fitzgerald
Boehringer Ingelheim
Argus Health
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot